Publicaciones en colaboración con investigadores/as de Ikerbasque, Fundación Vasca para la Ciencia (34)

2024

  1. A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer

    Breast Cancer Research, Vol. 26, Núm. 1

  2. Acetyl-CoA carboxylase 1 controls a lipid droplet–peroxisome axis and is a vulnerability of endocrine-resistant eR+ breast cancer

    Science Translational Medicine, Vol. 16, Núm. 736

  3. Identification of miRNAs and Their Target Genes Associated with Sunitinib Resistance in Clear Cell Renal Cell Carcinoma Patients

    International Journal of Molecular Sciences, Vol. 25, Núm. 13

  4. Non-coding RNA and gene expression analyses of papillary renal neoplasm with reverse polarity (PRNRP) reveal distinct pathological mechanisms from other renal neoplasms

    Pathology, Vol. 56, Núm. 4, pp. 493-503

  5. Power of Light: Raman Spectroscopy and Machine Learning for the Detection of Lung Cancer

    ACS Omega, Vol. 9, Núm. 12, pp. 14084-14091

2023

  1. Identification of fatty acid amide hydrolase as a metastasis suppressor in breast cancer

    Nature Communications, Vol. 14, Núm. 1

2022

  1. Author Correction: PR-LncRNA signature regulates glioma cell activity through expression of SOX factors (Scientific Reports, (2018), 8, 1, (12746), 10.1038/s41598-018-30836-5)

    Scientific Reports

  2. Cholangiocarcinoma landscape in Europe: Diagnostic, prognostic and therapeutic insights from the ENSCCA Registry

    Journal of Hepatology, Vol. 76, Núm. 5, pp. 1109-1121

  3. Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment

    Journal of Clinical Investigation, Vol. 132, Núm. 7

2021

  1. Correction: Current and novel therapeutic opportunities for systemic therapy in biliary cancer (British Journal of Cancer, (2020), 123, 7, (1047-1059), 10.1038/s41416-020-0987-3)

    British Journal of Cancer

  2. Discovery and proof-of-concept study of nuclease activity as a novel biomarker for breast cancer tumors

    Cancers, Vol. 13, Núm. 2, pp. 1-16

  3. Identification of a dexamethasone mediated radioprotection mechanism reveals new therapeutic vulnerabilities in glioblastoma

    Cancers, Vol. 13, Núm. 2, pp. 1-23

  4. Integrated mrna and mirna transcriptomic analyses reveals divergent mechanisms of sunitinib resistance in clear cell renal cell carcinoma (Ccrcc)

    Cancers, Vol. 13, Núm. 17

  5. The pseudokinase TRIB3 negatively regulates the HER2 receptor pathway and is a biomarker of good prognosis in luminal breast cancer

    Cancers, Vol. 13, Núm. 21

2020

  1. Current and novel therapeutic opportunities for systemic therapy in biliary cancer

    British Journal of Cancer, Vol. 123, Núm. 7, pp. 1047-1059

  2. Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

    Scientific Reports, Vol. 10, Núm. 1

  3. Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

    International Journal of Cancer, Vol. 147, Núm. 5, pp. 1315-1324

  4. The urinary transcriptome as a source of biomarkers for prostate cancer

    Cancers, Vol. 12, Núm. 2

2019

  1. Liquid biopsy in glioblastoma: Opportunities, applications and challenges

    Cancers, Vol. 11, Núm. 7

  2. Therapeutic relevance of SOX9 stem cell factor in gastric cancer

    Expert Opinion on Therapeutic Targets, Vol. 23, Núm. 2, pp. 143-152